Effect of hyperbilirubinemia on intestinal permeability in healthy term newborns

Direct hyperbilirubinemia in newborns with gastroschisis

BACKGROUND

Patients with gastroschisis and prolonged total (or partial) parenteral nutrition (PN) commonly develop direct hyperbilirubinemia (DH).

OBJECTIVE

To quantify the prevalence and severity of DH in newborns with gastroschisis and characterize the diagnostic work-up for DH in this patient population.

DESIGN/METHODS

Retrospective chart review of patients born with gastroschisis between 2005 and 2015 for the first 6 months of life.

RESULTS

29 patients were identified with gastroschisis. Mean gestational age and birthweight were 36.4 (± 1.8) weeks and 2.5 (± 0.6) kg. 41% were treated with primary reduction versus staged closure. Peak total and direct bilirubin (DB) levels were 10.17 ± 6.21 mg/dL and 5.58 ± 3.94 mg/dL, respectively. 23 patients (79.3%) were diagnosed with DH and 78.2% underwent additional work-up for hyperbilirubinemia consisting of imaging and laboratory studies, none of which revealed a cause for DH other than the presumed PN-associated cholestasis. In all patients, DB began to decline within 1-10 days of initiation of enteral feeds.

CONCLUSION(S)

DH is common in patients with gastroschisis and is unlikely to be associated with pathology aside from PN. Additional work-up may lead to unnecessary resource utilization.

LEVELS OF EVIDENCE

Case series with no comparison group, Level IV.

Ex vivo gut culture for studying differentiation and migration of small intestinal epithelial cells

Epithelial cultures are commonly used for studying gut health. However, due to the absence of mesenchymal cells and gut structure, epithelial culture systems including recently developed three-dimensional organoid culture cannot accurately represent in vivo gut development, which requires intense cross-regulation of the epithelial layer with the underlying mesenchymal tissue. In addition, organoid culture is costly. To overcome this, a new culture system was developed using mouse embryonic small intestine. Cultured intestine showed spontaneous peristalsis, indicating the maintenance of the normal gut physiological structure. During 10 days of ex vivo culture, epithelial cells moved along the gut surface and differentiated into different epithelial cell types, including enterocytes, Paneth cells, goblet cells and enteroendocrine cells. We further used the established ex vivo system to examine the role of AMP-activated protein kinase (AMPK) on gut epithelial health. Tamoxifen-induced AMPKα1 knockout vastly impaired epithelial migration and differentiation of the developing ex vivo gut, showing the crucial regulatory function of AMPK α1 in intestinal health.

Neonatal hyperbilirubinaemia: time for Italian recommendations?

The introduction of effective therapies for hyperbilirubinemia might have led to a general overconfidence among neonatal healthcare providers. National guidelines have been issued in many countries though they hardly stand the challenge of evidence-based medicine. A comparative appraisal shows significant discrepancies among different documents. As new, compelling evidence sheds a different light on bilirubin toxicity, this heterogeneity that borders confusion should be solved by implementing both clinical and basic research on the complex issue of neonatal hyperbilirubinemia.

Why should we care about neonatal hyperbilirubinemia in 2011?

Recent research links serum bilirubin levels to a positive function in human health. Yet in the neonate hyperbilirubinemia is associated to damage to the CNS and beyond. This article summarizes the evidence for the double edged role of bilirubin with a focus on the neonatal period. Also we briefly describe some of the current shortcomings in the treatment of neonatal hyperbilirubinemia.

Maturation of gastric electrical activity, gastric emptying and intestinal permeability in preterm newborns during the first month of life

INTRODUCTION

Immaturity of motility, intestinal epithelial barrier function and absorptive capacity may play a role in the pathophysiology of intestinal diseases in preterms. We determined the gastric electrical activity and emptying, and intestinal permeability, in preterm newborns to verify if a maturation pattern exists in preterm newborns during the first month of life.

PATIENTS AND METHODS

Eighteen preterm newborns (median 34 wks, range 2 wks) completed the study. They underwent the recording of gastric electrical activity by means of cutaneous electrogastrography, the ultrasound examination of gastric emptying, and the lactulose-to-mannitol ratio from permeability-absorption test on days 3, 7, 15, and 30 after birth.

RESULTS

Gastric electrical activity and emptying showed only slight changes between day 3 and day 7. On the contrary, an evident maturation in permeability, expressed as L/Mratio, was evident over time (Friedman Repeated Measures Analysis, p = 0.004).

CONCLUSION

In preterm healthy newborns of 34 weeks gestational age, electrical and motor activity are completely developed at birth whilst the intestinal epithelial barrier clearly improves during the first week of life.

Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease

The purpose of this study was to investigate and compare the specificity, sensitivity, and area under curve (AUC) of the lactulose/mannitol ratio, lactulose/creatinine ratio, and lactulose recovery and their diagnostic value for intestinal permeability assessment within the absorption lactulose/mannitol (L/M) test.

RESULTS

The value of the lactulose/mannitol ratio, lactulose/creatinine ratio, and the percentage of lactulose recovery in Crohn's disease (0.0763 +/- 0.0369; 99.62 +/- 67.87; 1.0478 +/- 0.6148) and in liver cirrhosis (0.0517 +/- 0.0365; 54.65 +/- 53.26; 0.838 +/- 0.929) were significantly different from the values measured in the control group (0.0123 +/- 0.0081; 10.95 +/- 7.07; 0.2438 +/- 0.1568), P < 0.0001-0.002). In Crohn's disease, specificity, sensitivity, and AUC were 100%, 89.5%, and 0.987, respectively, of the lactulose/mannitol ratio at a cut-off level of 0.022. In liver cirrhosis, the test characteristics were 88.5%, 84.2%, and 0.910 at a cut-off level of 0.018.

CONCLUSION

The lactulose/mannitol ratio was evaluated to have the highest diagnostic value to assess intestinal permeability.

Neonatal hyperbilirubinemia increases intestinal protein permeability and the prevalence of cow's milk protein intolerance

AIMS

Bilirubin is a newly discovered modulator of the gut barrier in vitro and in vivo. We studied the effect of bilirubin on the serosal to mucosal intestinal permeability in vivo. We also investigated the prevalence of cow's milk protein intolerance (CMPI) in infants with moderate hyperbilirubinemia versus matched controls.

METHODS

Faecal alpha 1 antitrypsin (a1AT) was used to monitor intestinal protein loss; a large cohort was prospectively followed for 12 months for sign and symptoms of CMPI.

RESULTS

Neonates with hyperbilirubinemia had higher stool excretion of a1AT than controls (0.68 +/- 0.28 mg/g vs. 0.25 +/- 0.11 mg/g; p < 0.01). Faecal a1AT correlates with total serum bilirubin (TSB) (r = 0.85; p < 0.01). Also, in the first 12 months of life, formerly hyperbilirubinemic infants had an higher prevalence of CMPI (14/353 vs. 4/339; chi2= 4.018, p = 0.045).

CONCLUSIONS

Neonatal hyperbilirubinemia increases stool protein loss and is also a mild risk factor for CMPI.